Ocugen said the U.S. Food and Drug Administration (FDA) declined to issue an emergency use authorization for Covaxin, the COVID-19 vaccine developed by its Indian partner Bharat Biotech, for children.
The biopharmaceutical company said it intends to continue working with the FDA to evaluate the process for getting an emergency use authorization for pediatric use of Covaxin, it said in a March 4 statement that announced the health agency’s decision. The company had sought to authorize the shot for children aged 2 to 18.
